CIK 0000875045
- Large accelerated filer
BIOGEN INC.
Sign in to watch- Ticker
- BIIB
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 330112644
- Phone
- +1 617-679-2000
- Business address
- 225 BINNEY STREET, CAMBRIDGE, MA, 02142
- Former names
- BIOGEN IDEC INC., BIOGEN IDEC INC, IDEC PHARMACEUTICALS CORP / DE, IDEC PHARMACEUTICALS CORP / CA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-03-01 | McKenzie Paul EVP Pharmaceutical Oper & Tech | Other disposition · Restricted Stock Unit | −363 | 1,692 | ||
| 2017-03-01 | Sandrock Alfred EVP CMO Neuro & Neurodegenerat | Sale | −973 | $290.07 | $282K | 9,040.86 |
| 2017-02-28 | Clancy Paul J Executive VP and CFO | Exercise or conversion | +663 | 27,533 | ||
| 2017-02-28 | Clancy Paul J Executive VP and CFO | Shares withheld for taxes | −312 | $284.75 | $89K | 27,221 |
| 2017-02-28 | Clancy Paul J Executive VP and CFO | Exercise or conversion | +2,092 | 29,313 | ||
| 2017-02-28 | Clancy Paul J Executive VP and CFO | Shares withheld for taxes | −847 | $287.63 | $244K | 28,466 |
| 2017-02-28 | Clancy Paul J Executive VP and CFO | Exercise or conversion | +1,152 | 29,618 | ||
| 2017-02-28 | Clancy Paul J Executive VP and CFO | Shares withheld for taxes | −543 | $274.76 | $149K | 29,075 |
| 2017-02-28 | Clancy Paul J Executive VP and CFO | Exercise or conversion | +2,873 | 31,948 | ||
| 2017-02-28 | Clancy Paul J Executive VP and CFO | Shares withheld for taxes | −1,352 | $274.76 | $371K | 30,596 |
| 2017-02-28 | Clancy Paul J Executive VP and CFO | Other disposition · Restricted Stock Unit | −1,352 | 1,152 | ||
| 2017-02-28 | Clancy Paul J Executive VP and CFO | Other disposition · Restricted Stock Unit | −1,678 | 9,638 | ||
| 2017-02-28 | Clancy Paul J Executive VP and CFO | Other disposition · Restricted Stock Unit | −1,105 | 2,437 | ||
| 2017-02-28 | Clancy Paul J Executive VP and CFO | Exercise or conversion · Restricted Stock Unit | −663 | 1,774 | ||
| 2017-02-28 | Clancy Paul J Executive VP and CFO | Exercise or conversion · Restricted Stock Unit | −2,092 | 7,546 | ||
| 2017-02-28 | Clancy Paul J Executive VP and CFO | Exercise or conversion · Restricted Stock Unit | −1,152 | 0 | ||
| 2017-02-28 | Clancy Paul J Executive VP and CFO | Exercise or conversion · Restricted Stock Unit | −2,873 | 0 | ||
| 2017-02-28 | Sandrock Alfred EVP CMO Neuro & Neurodegenerat | Exercise or conversion | +1,375 | 9,584.86 | ||
| 2017-02-28 | Sandrock Alfred EVP CMO Neuro & Neurodegenerat | Shares withheld for taxes | −647 | $287.63 | $186K | 8,937.86 |
| 2017-02-28 | Sandrock Alfred EVP CMO Neuro & Neurodegenerat | Exercise or conversion | +398 | 9,335.86 |
Page 63 of 73 · 1,456 trades